Guggenheim Capital LLC Novavax Inc Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Novavax Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 68,763 shares of NVAX stock, worth $580,359. This represents 0.01% of its overall portfolio holdings.
Number of Shares
68,763
Previous 55,404
24.11%
Holding current value
$580,359
Previous $701,000
23.82%
% of portfolio
0.01%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding NVAX
# of Institutions
287Shares Held
94.6MCall Options Held
6.95MPut Options Held
9.4M-
Vanguard Group Inc Valley Forge, PA15.4MShares$130 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.8MShares$100 Million0.0% of portfolio
-
Shah Capital Management11.1MShares$94.1 Million35.54% of portfolio
-
State Street Corp Boston, MA7.69MShares$64.9 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.94MShares$50.1 Million0.07% of portfolio
About NOVAVAX INC
- Ticker NVAX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,215,104
- Market Cap $660M
- Description
- Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...